Ing Groep Nv Gilead Sciences, Inc. Transaction History

Ing Groep Nv

$16.5 Billion
Q3 2024

A detailed history of Ing Groep Nv transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ing Groep Nv holds 392,685 shares of GILD stock, worth $36.4 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

392,685

Previous 282,897 38.81%

Holding current value

$36.4 Million

Previous $19.4 Million 69.58%

% of portfolio

0.2%

Previous 0.12%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$66.59 - $83.99 $7.31 Million - $9.22 Million	109,788 Added 38.81%	392,685 $32.9 Million
Q2 2024 Aug 13, 2024	SELL	$63.15 - $72.88 $1.2 Million - $1.39 Million	-19,031 Reduced 6.3%	282,897 $19.4 Million
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $45.1 Million - $55 Million	-630,040 Reduced 67.6%	301,928 $22.1 Million
Q4 2023 Feb 08, 2024	BUY	$73.27 - $83.09 $33.5 Million - $38 Million	457,847 Added 96.57%	931,968 $75.5 Million
Q3 2023 Oct 27, 2023	SELL	$73.94 - $80.67 $22.2 Million - $24.3 Million	-300,791 Reduced 38.82%	474,121 $35.5 Million
Q2 2023 Aug 07, 2023	BUY	$76.01 - $86.7 $40.6 Million - $46.3 Million	534,194 Added 221.92%	774,912 $59.7 Million
Q1 2023 May 09, 2023	SELL	$77.31 - $88.08 $7.32 Million - $8.34 Million	-94,714 Reduced 28.24%	240,718 $20 Million
Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $2.91 Million - $4.18 Million	46,694 Added 16.17%	335,432 $28.8 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1.65 Million - $1.88 Million	-27,709 Reduced 8.76%	288,738 $17.8 Million
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $2.12 Million - $2.39 Million	36,811 Added 13.16%	316,447 $19.6 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $3.18 Million - $3.98 Million	54,889 Added 24.42%	279,636 $16.6 Million
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $5.92 Million - $6.72 Million	91,288 Added 68.4%	224,747 $16.3 Million
Q3 2021 Nov 02, 2021	BUY	$67.69 - $73.03 $186,012 - $200,686	2,748 Added 2.1%	133,459 $9.32 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $2.66 Million - $2.91 Million	41,923 Added 47.22%	130,711 $9 Million
Q1 2021 May 12, 2021	BUY	$60.0 - $68.46 $218,580 - $249,399	3,643 Added 4.28%	88,788 $5.74 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $3.14 Million - $3.58 Million	55,398 Added 186.23%	85,145 $4.96 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $1.02 Million - $1.29 Million	16,488 Added 124.35%	29,747 $1.88 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $9.47 Million - $11 Million	-130,973 Reduced 90.81%	13,259 $1.02 Million
Q1 2020 May 06, 2020	BUY	$62.63 - $80.22 $3.68 Million - $4.71 Million	58,773 Added 68.77%	144,232 $10.8 Million
Q4 2019 Feb 10, 2020	BUY	$61.62 - $67.78 $395,785 - $435,350	6,423 Added 8.13%	85,459 $5.55 Million
Q3 2019 Nov 08, 2019	SELL	$62.51 - $69.0 $18.7 Million - $20.7 Million	-299,719 Reduced 79.13%	79,036 $5.01 Million
Q2 2019 Aug 12, 2019	BUY	$61.87 - $69.38 $18,375 - $20,605	297 Added 0.08%	378,755 $25.6 Million
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $2.47 Million - $2.77 Million	39,568 Added 11.68%	378,458 $24.6 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $209,226 - $273,024	3,456 Added 1.03%	338,890 $21.2 Million
Q3 2018 Nov 06, 2018	BUY	$71.28 - $78.92 $905,256 - $1 Million	12,700 Added 3.94%	335,434 $25.9 Million
Q2 2018 Aug 10, 2018	BUY	$64.88 - $75.68 $15.3 Million - $17.9 Million	236,424 Added 273.92%	322,734 $22.9 Million
Q1 2018 May 07, 2018	BUY	$72.84 - $88.8 $5.97 Million - $7.28 Million	82,008 Added 1906.28%	86,310 $6.51 Million
Q4 2017 Feb 06, 2018	SELL	$71.15 - $83.52 $33.5 Million - $39.3 Million	-470,389 Reduced 99.09%	4,302 $308,000
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $34.2 Million - $40.6 Million	474,691	474,691 $38.5 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.

Account